EP1322325A4 - Inhibition der prozessierung und replikation des hepatitis c virus - Google Patents

Inhibition der prozessierung und replikation des hepatitis c virus

Info

Publication number
EP1322325A4
EP1322325A4 EP01952780A EP01952780A EP1322325A4 EP 1322325 A4 EP1322325 A4 EP 1322325A4 EP 01952780 A EP01952780 A EP 01952780A EP 01952780 A EP01952780 A EP 01952780A EP 1322325 A4 EP1322325 A4 EP 1322325A4
Authority
EP
European Patent Office
Prior art keywords
replication
inhibiting hepatitis
virus processing
virus
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01952780A
Other languages
English (en)
French (fr)
Other versions
EP1322325A1 (de
Inventor
Lloyd H Waxman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1322325A1 publication Critical patent/EP1322325A1/de
Publication of EP1322325A4 publication Critical patent/EP1322325A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
EP01952780A 2000-07-20 2001-07-16 Inhibition der prozessierung und replikation des hepatitis c virus Withdrawn EP1322325A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21955000P 2000-07-20 2000-07-20
US219550P 2000-07-20
PCT/US2001/022335 WO2002007761A1 (en) 2000-07-20 2001-07-16 Inhibiting hepatitis c virus processing and replication

Publications (2)

Publication Number Publication Date
EP1322325A1 EP1322325A1 (de) 2003-07-02
EP1322325A4 true EP1322325A4 (de) 2004-09-15

Family

ID=22819717

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01952780A Withdrawn EP1322325A4 (de) 2000-07-20 2001-07-16 Inhibition der prozessierung und replikation des hepatitis c virus

Country Status (4)

Country Link
EP (1) EP1322325A4 (de)
JP (1) JP2004504356A (de)
CA (1) CA2416603A1 (de)
WO (1) WO2002007761A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030046397A (ko) * 2000-07-28 2003-06-12 슬로안-케테링인스티튜트퍼캔서리서치 세포증식성 질환 및 바이러스 감염의 치료 방법
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
DE10361944A1 (de) * 2003-12-31 2005-07-28 Viromics Gmbh Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
JP4143669B2 (ja) 2004-02-24 2008-09-03 日本たばこ産業株式会社 ４環縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
DE102005009440A1 (de) 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007058384A1 (en) * 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
JP2007238442A (ja) * 2006-02-07 2007-09-20 Hiroshi Takaku 抗ウイルス剤
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
DE102007041116A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-Dihydro-isoindolderivate
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
US9149463B2 (en) 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
WO2010107742A2 (en) * 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
US8940730B2 (en) 2007-09-18 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a Flaviviridae family viral infection
JP5715820B2 (ja) 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
DE102008061214A1 (de) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
DE102009054302A1 (de) 2009-11-23 2011-05-26 Merck Patent Gmbh Chinazolinderivate
DE102010046837A1 (de) 2010-09-29 2012-03-29 Merck Patent Gmbh Phenylchinazolinderivate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1189340A (zh) * 1997-01-28 1998-08-05 陶佩珍 格尔德霉素的新型广谱抗病毒应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1189340A (zh) * 1997-01-28 1998-08-05 陶佩珍 格尔德霉素的新型广谱抗病毒应用

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
AN W G ET AL: "DEPLETION OF P185ERBB2, RAF-1 AND MUTANT P53 PROTEINS BY GELDANAMYCIN DERIVATIVES CORRELATES WITH ANTIPROLIFERATIVE ACTIVITY", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 40, no. 1, 1997, pages 60 - 64, XP001153415, ISSN: 0344-5704 *
DARKE P L ET AL: "INHIBITION OF HEPATITIS C VIRUS NS2/3 PROCESSING BY NS4A PEPTIDES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 49, 3 December 1999 (1999-12-03), pages 34511 - 34514, XP002934074, ISSN: 0021-9258 *
DATABASE WPI Section Ch Week 200273, Derwent World Patents Index; Class B04, AN 2002-675594, XP002287486 *
HU JIANMING ET AL: "Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 16, no. 1, 1997, pages 59 - 68, XP002287484, ISSN: 0261-4189 *
HU JIANMING ET AL: "Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 3, 1996, pages 1060 - 1064, XP002287483, ISSN: 0027-8424 *
NAKAGAWA S. ET AL: "Hsp90 inhibitors suppress HCV replication in replicaon cells and humanized liver mice", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 353, 2007, pages 882 - 888 *
PIERONI LUISA ET AL: "In vitro study of the NS2-3 protease of hepatitis C virus", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 9, September 1997 (1997-09-01), pages 6373 - 6380, XP002184058, ISSN: 0022-538X *
ROE S.M. ET AL: "Structural basis for inhbtion of the Hsp90molecular chaperone by the antitumor antibiotics radicicol and geldanamycin", JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 2, 1999, pages 260 - 266 *
SCHEIBEL T.; BUCHNER J.: "The Hsp90 complex - a super-chaperone machine as anovel drug target", BIOCHEMICAL PHARMACOLOGY, vol. 56, no. 6, 1998, pages 675 - 682 *
SCHULTE T W ET AL: "THE BENZOQUINONE ANSAMYCIN 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN BINDS TO HSP90 AND SHARES IMPORTANT BIOLOGIC ACTIVITIES WITH GELDANAMYCIN", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 42, 1998, pages 273 - 279, XP002949121, ISSN: 0344-5704 *
See also references of WO0207761A1 *
SOGA SHIRO ET AL: "KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules", CANCER RESEARCH, vol. 59, no. 12, 15 June 1999 (1999-06-15), pages 2931 - 2938, XP002287485, ISSN: 0008-5472 *
VALL¹E S. ET AL: "Ribavirin-induced resistance to heat shock, inhibition of the Ras.Raf-1 pathway and arrest in G1", EURROPEAN JOURNAL OF PHARMACOLOGY, vol. 404, 2000, pages 49 - 62 *
WAXMAN LLOYD ET AL: "Host cell factor requirement for hepatitis C virus enzyme maturation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 24, 20 November 2001 (2001-11-20), November 20, 2001, pages 13931 - 13935, XP002287099, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
JP2004504356A (ja) 2004-02-12
EP1322325A1 (de) 2003-07-02
WO2002007761A1 (en) 2002-01-31
CA2416603A1 (en) 2003-01-31

Similar Documents

Publication Publication Date Title
EP1322325A4 (de) Inhibition der prozessierung und replikation des hepatitis c virus
AP2006003817A0 (en) methods and compositions for treating hepatitis C virus
GB2366692B (en) Virus protection in an internet environment
HUP0500456A3 (en) Hepatitis c tripeptide inhibitors, pharmaceutical compositions comprising thereof and their use
AU9667901A (en) Mycoattractants and mycopesticides
GB2337755B (en) Virus vaccine
EP1346724A4 (de) Mittel zur behandlung von hepatitis c
AUPQ912000A0 (en) Improved virus like particles
IL153879A0 (en) Modified virus
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
AU2001290629A1 (en) Heat shock response and virus replication
EP1307211A4 (de) Immunmediatoren und verwandte methoden
IL143798A0 (en) Hepatitis c virus ns3 protease
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
AU9279601A (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
AU4529401A (en) Aids ancestral viruses and vaccines
EP1113777A4 (de) Neues hepatitis c viruspeptid und seine verwendung
HK1052811A1 (en) Selective inactivation and copy protection
IL139269A0 (en) Hepatitis vaccine
GB0001475D0 (en) Virus strains
IL149314A0 (en) Agent for treating hepatitis c
GB2366717B (en) Placemat and coaster set
GB2368960B (en) Transaction processing
GB0126212D0 (en) Placemat and coaster set

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030220

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/365 B

Ipc: 7A 61K 31/395 B

Ipc: 7A 01N 43/42 B

Ipc: 7A 61K 39/385 B

Ipc: 7A 01N 43/40 B

Ipc: 7A 61K 31/00 B

Ipc: 7A 61K 39/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040729

RTI1 Title (correction)

Free format text: INHIBITING HEPATITIS C VIRUS PROCESSING AND REPLICATION WITH HSP90 INHIBITORS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080201